United Kingdom

Book a consultation
Explore InnoFund

Sector expertise

R&D Tax Credits for Pharmaceutical Companies

Pharmaceutical businesses undertake scientific and technological development across formulation, delivery, analytical methods, stability, manufacturing and scale-up. Work may qualify for R&D Tax Credits where competent professionals must investigate uncertainty in safety, efficacy, performance, reproducibility or production.

Book a consultation Explore this sector

Innovation in pharmaceuticals

Pharmaceuticals businesses solve technical problems every day.

Pharmaceutical innovation depends on controlled experimentation and evidence. Qualifying work may extend beyond discovery into formulation, analytical development, process engineering, delivery systems and reliable transfer into manufacture.

This includes work across:

  • Drug formulation
  • Delivery systems
  • Analytical methods
  • Stability and shelf life
  • Process development
  • Manufacturing scale-up
  • Clinical trial technology
  • Quality by design
  • Combination products
  • Packaging interaction
  • Data and modelling
  • Sustainable production

Qualifying R&D may arise where a business is not simply applying known methods, but is testing, adapting or developing a new approach because the scientific or technological answer is uncertain.

Speak with a consultant
Chemicals innovation activity that may qualify for R&D Tax Credits

Qualifying R&D

How pharmaceutical businesses can qualify for R&D Tax Credits.

Qualifying R&D can arise where a project seeks an advance in science or technology and competent professionals must carry out systematic work to resolve genuine technical uncertainty.

  • Developing and reformulating products Uncertainty in solubility, stability, bioavailability or excipient interaction can require qualifying scientific investigation.
  • Creating analytical methods R&D may arise where existing methods cannot deliver the required sensitivity, selectivity, accuracy or robustness.
  • Improving drug delivery Projects involving controlled release, devices or routes of administration may qualify where performance is uncertain.
  • Resolving stability and packaging interactions Testing degradation, compatibility and environmental exposure can involve qualifying technical uncertainty.
  • Scaling laboratory processes Moving into pilot or commercial manufacture may create uncertainty in yield, control, mixing, transfer or reproducibility.
  • Developing manufacturing and quality systems New process controls and data-led approaches may qualify where standard practice cannot meet required performance.
Discuss your R&D activity

A note from Dr Jack Brent

Pharmaceuticals R&D claims need clear technical evidence.

Pharmaceuticals projects can look like routine commercial delivery from the outside, even when the team has worked through difficult scientific or technological uncertainty. A defensible claim must identify the advance sought, the available baseline and why a competent professional could not readily determine the solution.

InnoFund separates ordinary delivery from the qualifying work and connects the technical narrative to contemporaneous evidence and eligible expenditure. That produces a focused claim that can withstand HMRC scrutiny.

Dr Jack Brent, Senior R&D Tax Manager at InnoFund
  • ATT — Association of Tax Technicians

Dr Jack Brent

Senior R&D Tax Manager

  • PhD in Materials Science and MChem in Chemistry.
  • ATT qualified with detailed knowledge of the UK R&D tax regime.
  • Research experience across advanced materials, battery technology and solar energy harvesting.
Speak to Dr Jack Brent

Client experience

Pharmaceuticals Companies Recommend InnoFund

Practical support from a multidisciplinary team that understands both the technical work and the claim.

“Would highly recommend, they know their stuff! They assisted greatly with an R&D claim rejection by HMRC.”

Steven Potts

Finance Director, Sigma Polymers

“Excellent from start to finish, lovely team and a great result. Highly recommended.”

Sam Collins

General Manager, Terra Farmer

Clear boundaries

Not every pharmaceuticals project qualifies.

Commercial value, novelty or project difficulty do not qualify a project on their own. Examples of work that may fall outside the scheme include:

  • Routine delivery using established methods
  • Standard installation or configuration
  • Ordinary maintenance and repair
  • Commercial or cosmetic changes
  • Routine quality control
  • Straightforward replication of an existing solution
  • General project management
  • Work completed after technical uncertainty was resolved

Many projects contain a mixture of qualifying and non-qualifying activity. InnoFund identifies the technical boundary so the claim remains accurate and proportionate.

Eligible expenditure

Eligible R&D costs for pharmaceutical businesses.

Costs directly connected to qualifying activity may include:

  • Staff time spent on qualifying R&D
  • Employer National Insurance and pension contributions
  • Subcontracted R&D, where eligible
  • Externally provided workers
  • Software, cloud computing and data costs used for R&D
  • Materials and consumables used in trials
  • Prototype components and testing costs
  • Technical consultancy, where eligible

We trace expenditure back to the qualifying work and apply the rules relevant to the company, contract and accounting period.

Evidence & scrutiny

HMRC risk areas for pharmaceuticals R&D claims.

A strong claim explains the science or technology rather than relying on broad statements about innovation. Common risk areas include:

  • Claiming commercial complexity rather than technical uncertainty
  • No clear baseline of existing science or technology
  • Routine work presented as R&D
  • Weak records of trials, failures and iteration
  • Incorrect treatment of subcontracted or customer-funded work
  • No competent professional input
  • Overclaiming whole projects instead of qualifying activity
  • Unclear project and cost boundaries

InnoFund reviews both the technical position and the expenditure so each claim is clear, evidence-led and defensible.

Assess your project

Questions, answered

Clear, practical answers to the questions businesses ask most often.

Yes. Pharmaceutical businesses can claim where a project seeks an advance in science or technology and competent professionals must resolve genuine technical uncertainty through systematic work.

Qualifying work may include Drug formulation, Delivery systems, Analytical methods, Stability and shelf life, Process development, Manufacturing scale-up. Eligibility depends on the technical advance sought and the uncertainty encountered, not simply the commercial value of the project.

They can. A project does not have to succeed, and prototypes or failed trials can provide strong evidence that the outcome was not readily deducible at the outset. The work must still form part of a systematic attempt to resolve technical uncertainty.

Yes, where the business has to develop or materially adapt technology rather than simply buy, configure or use an established solution. The claim should explain the performance gap, technical uncertainty and work undertaken to resolve it.

Eligible expenditure may include qualifying staff costs, employer contributions, software, cloud and data costs, consumables, prototype materials, externally provided workers and some subcontracted R&D. The exact treatment depends on the accounting period and scheme rules.

Useful evidence includes design records, test results, trial data, technical notes, project plans, calculations, software logs, photographs, failure records, meeting notes, cost records and explanations from the competent professionals who led the work.

Other innovation funding services

Your next step

Don’t guess. Know for sure.

Got a project you want to discuss? InnoFund separates routine delivery from genuine R&D so claims are accurate, compliant and properly evidenced.

Book a consultation
  • 30 minutes
  • Expert guidance
  • Commitment free
InnoFund adviser discussing R&D Tax Credits with a telecommunications business